1499193-61-1

Basic information

• Product Name: 5-Azaspiro[2.4]heptane-5,6-dicarboxylic acid, 6-[2-(7-broMo-9,9-difluoro-9H-fluoren-2-yl)-2-oxoethyl] 5-(1,1-diMethylethyl) ester, (6S)-
• Synonyms: 5-Azaspiro[2.4]heptane-5,6-dicarboxylic acid, 6-[2-(7-broMo-9,9-difluoro-9H-fluoren-2-yl)-2-oxoethyl] 5-(1,1-diMethylethyl) ester, (6S)-;(S)-6-(2-(7-bromo-9,9-difluoro-9H-fluoren-2-yl)-2-oxoethyl) 5-tert-butyl 5-azaspiro[2.4]heptane-5,6-dicarboxylate
• CAS NO: 1499193-61-1
• Molecular Formula: C27H26BrF2NO5
• Molecular Weight: 562.3998464
• Mol File: 1499193-61-1.mol

Chemical Properties

• Boiling Point: 617.5±55.0 °C(Predicted)
• Appearance: /
• Density: 1.52±0.1 g/cm3(Predicted)
• PKA: -3.06±0.40(Predicted)
• CAS DataBase Reference: 5-Azaspiro[2.4]heptane-5,6-dicarboxylic acid, 6-[2-(7-broMo-9,9-difluoro-9H-fluoren-2-yl)-2-oxoethyl] 5-(1,1-diMethylethyl) ester, (6S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Azaspiro[2.4]heptane-5,6-dicarboxylic acid, 6-[2-(7-broMo-9,9-difluoro-9H-fluoren-2-yl)-2-oxoethyl] 5-(1,1-diMethylethyl) ester, (6S)-(1499193-61-1)
• EPA Substance Registry System: 5-Azaspiro[2.4]heptane-5,6-dicarboxylic acid, 6-[2-(7-broMo-9,9-difluoro-9H-fluoren-2-yl)-2-oxoethyl] 5-(1,1-diMethylethyl) ester, (6S)-(1499193-61-1)

Safety Data

• Hazardous Substances Data: 1499193-61-1(Hazardous Substances Data)

Upstream product

• 1129634-44-1 (6S)-5-[(tert-butoxy)carbonyl]-5-azaspiro[2.4]heptane-6-carboxylic acid 
• 1378387-81-5 1-(7-bromo-9,9-difluoro-9-hydrofluoren-2-yl)-2-chloroethanone 
• 1441673-92-2 (S)-5-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptane-6-carboxylate 
• 84348-38-9 (S)-1-(tert-butoxycarbonyl)-4-methylenepyrrolidine-2-carboxylic acid 
• 123348-27-6 2-bromo-7-iodofluorene 
• 1133-80-8 2-bromo-9H-fluorene 
• 1412903-77-5 (6S)-1,1-dibromo-5-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptane-6-carboxylic acid 
• 1454843-77-6 (±)-5-(tert-butoxycarbonyl)-5-azaspiro[2.4]heptane-6-carboxylic acid 
• 136476-38-5 cyclopropane-1,1-diylbis(methylene) dimethanesulfonate 
• 83321-23-7 1,1-bis(iodomethyl)cyclopropane 
• 39590-81-3 [1-(hydroxymethyl)cyclopropyl]methanol 

Relevant articles and documents

Ledipasvir preparation method

The invention discloses a Ledipasvir preparation method. The Ledipasvir preparation method includes steps: (1) Ledipasvir intermediate product 1-LD-B preparation; (2) Ledipasvir intermediate product 2-LD-E preparation; (3) Ledipasvir intermediate product 3-LD-F preparation; (4) Ledipasvir intermediate product 4-LD-J preparation; (5) Ledipasvir intermediate product 5-LD-L preparation; (6) Ledipasvir-LD-Q preparation. The Ledipasvir preparation method has advantages of technical maturity and stability, product quality stability, safety and reliability in production process and suitableness for industrial production.

Preparation method of Ledipasvir

The invention discloses a preparation method of Ledipasvir. The method has no need for chromatographic column separation, reduces the cost of raw materials, and can acquire a high purity product by a simple precipitation or crystallization purification means, thus providing feasible technical conditions for large-scale industrial production.

Hepatitis C virus inhibitor, medical composition and application thereof

The invention provides a hepatitis C virus inhibitor, a medical composition and application thereof. The hepatitis C virus inhibitor is a compound as shown in a formula (I), or salt, hydrate or a solvent compound accepted in crystal forms and pharmacy. The compound disclosed by the invention has better hepatitis C viral protein NS5A restraining activity, has better pharmacodynamics/pharmacokinetics properties, is good in applicability and high in safety, can be used for preparing medicines for treating hepatitis C virus infection, and has favorable market development prospects.

Discovery of ledipasvir (GS-5885): A potent, once-daily oral NS5A inhibitor for the treatment of hepatitis C virus infection

A new class of highly potent NS5A inhibitors with an unsymmetric benzimidazole-difluorofluorene-imidazole core and distal [2.2.1]azabicyclic ring system was discovered. Optimization of antiviral potency and pharmacokinetics led to the identification of 39 (ledipasvir, GS-5885). Compound 39 (GT1a replicon EC50 = 31 pM) has an extended plasma half-life of 37-45 h in healthy volunteers and produces a rapid >3 log viral load reduction in monotherapy at oral doses of 3 mg or greater with once-daily dosing in genotype 1a HCV-infected patients. 39 has been shown to be safe and efficacious, with SVR12 rates up to 100% when used in combination with direct-acting antivirals having complementary mechanisms.

SYNTHESIS OF ANTIVIRAL COMPOUND

The present disclosure provides processes for the preparation of a compound of formula I: which is useful as an antiviral agent. The disclosure also provides compounds that are synthetic intermediates to compounds of formula I.

SOLID FORMS OF AN ANTIVIRAL COMPOUND

Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5-(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro[2.4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: Also provided are processes of manufacture and methods of using the amorphous and crystalline forms.